5 Other operating income and expenses

January 1 - June 30

millions of CHF	2023	2022 1)
Proceeds received in the sale process of medmix Poland	2.0	–
Rental income from sub-leases	0.4	0.1
Gain from sale of property, plant and equipment	0.0	0.0
Operating currency exchange gains, net	0.0	–
Other operating income	0.3	0.1
Total other operating income	2.8	0.2

Restructuring expenses	–0.1	–0.5
Cost for mergers and acquisitions	–0.1	–
Loss from sale of property, plant and equipment	–0.1	–0.1
Operating currency exchange losses, net	–	–1.8
Deconsolidation of medmix Poland: Loss on net assets derecognized and retained investment	–	–15.4
Total other operating expenses	–0.3	–17.7

Total other operating income / (expenses), net	2.5	–17.6

1) The numbers as of June 30, 2022, have been adjusted following the deconsolidation of medmix Poland. A reconciliation to the previously published numbers is provided in note 14.

Other operating income includes income from litigation cases, government grants and incentives, and recharges to third parties not qualifying as revenues from customers.

In 2023, the group received an amount of CHF 2.0 million in the sale process of medmix Poland to a third party, resulting in a profit recognized in other operating income and a cash flow in the amount of CHF 2.0 million. The transaction is subject to regulatory approvals. For more details, reference is made to note 14.

In 2022, the group deconsolidated medmix Poland as of April 2022. The loss on the net assets derecognized and retained investment amounted to CHF 15.4 million. Amounts owed to and from medmix Poland before loss of control have been reclassified from intercompany receivables, loans and payables to third party receivables, loans and payables in the total net assets amount of CHF 11.8 million. For more details, reference is made to note 14.

For the period ended June 30, 2023, the group recognized restructuring costs of CHF 0.1 million (half year 2022: CHF 0.5 million).